Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tax Benefits, Branded Portfolio, Synergies Drive Actavis’ Acquisition of Warner Chilcott

Executive Summary

Actavis’ purchase of Warner Chilcott will lower the former’s overall tax rate significantly, expand its specialty pharma business to 25% of total revenues, and provide global critical mass – all necessary responses to a future that includes fewer opportunities for small molecule generics and greater pricing pressures.


Related Content

How US Tax Plan Could Affect Global Pharma Manufacturing Networks
Biotech And Specialty Pharma’s M&A Power Gains On Big Pharma, EY Report
Teva Loses 180-Day Exclusivity For Generic Actonel As FDA Stands Firm On Review Delays
Actavis’ Brent Saunders And Paul Bisaro Talk Innovation Vs. Discovery
Deals Of The Week Keeps Tabs As Tax Trimming Fuels Deal-Making
Deals Of The Week: Keeping Score – Valeant Wants Actavis, Which Covets Warner Chilcott …
Three Largest U.S. Generic Firms See Diversification As Best Path Through Reverse Patent Cliff
Warner Chilcott Takes Itself Off The Market; Special Dividend Disappoints
Waiting For Blockbusters: Osteoporosis Market Burdened With Black Box Warnings, Reimbursement Woes, And Spare Pipelines
Warner Chilcott’s Launch Of Atelvia Hits Headwinds


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts